XERIS BIOPHARMA HOLDINGS, INC. Operating Leases, Rent Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Operating Leases, Rent Expense of $700.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2023-03-08
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for the quarter ending 2022-09-30 was $700.00K, a 16.67% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for the quarter ending 2022-06-30 was $700.00K, a 16.67% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for the quarter ending 2022-03-31 was $700.00K, a 16.67% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for the quarter ending 2021-12-31 was $600.00K, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for fiscal 2021 was $2.40M, a 4.35% increase from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. operating leases, rent expense for fiscal 2020 was $2.30M.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $700.00K 10-Q · filed 2022-11-09 | $1.40M derived: sum of 2 quarters · filed 2022-11-09 | $2.20M 10-Q · filed 2022-11-09 | $2.70M derived: sum of 4 quarters · filed 2023-03-08 |
| 2022-06-30 | $700.00K 10-Q · filed 2022-08-10 | $1.40M 10-Q · filed 2022-08-10 | $2.00M derived: sum of 3 quarters · filed 2023-03-08 | $2.60M derived: sum of 4 quarters · filed 2023-03-08 |
| 2022-03-31 | $700.00K 10-Q · filed 2022-05-11 | $1.30M derived: sum of 2 quarters · filed 2023-03-08 | $1.90M derived: sum of 3 quarters · filed 2023-03-08 | $2.50M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.20M derived: sum of 2 quarters · filed 2023-03-08 | $1.80M derived: sum of 3 quarters · filed 2023-03-08 | $2.40M 10-K · filed 2023-03-08 |
| 2021-09-30 | $600.00K 10-Q · filed 2022-11-09 | $1.20M derived: sum of 2 quarters · filed 2022-11-09 | $1.80M 10-Q · filed 2022-11-09 | $2.40M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $600.00K 10-Q · filed 2022-08-10 | $1.20M 10-Q · filed 2022-08-10 | $1.80M derived: sum of 3 quarters · filed 2022-08-10 | $2.40M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $600.00K 10-Q · filed 2022-05-11 | $1.20M derived: sum of 2 quarters · filed 2022-05-11 | $1.80M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.20M derived: sum of 2 quarters · filed 2022-03-11 | $2.30M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $600.00K 10-Q · filed 2021-11-10 | $1.70M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |